IUPAC/Chemical Name
N-((1R)-2-Cyclohexyl-1-(((2S)-2-((3-guanidinopropyl)carbamoyl)piperidino)carbonyl)ethyl)glycine
InChi Key
CDPROXZBMHOBTQ-SJORKVTESA-N
InChi Code
InChI=1S/C21H38N6O4/c22-21(23)25-11-6-10-24-19(30)17-9-4-5-12-27(17)20(31)16(26-14-18(28)29)13-15-7-2-1-3-8-15/h15-17,26H,1-14H2,(H,24,30)(H,28,29)(H4,22,23,25)/t16-,17+/m1/s1
SMILES Code
O=C(O)CN[C@@H](C(N1[C@H](C(NCCCNC(N)=N)=O)CCCC1)=O)CC2CCCCC2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
438.57
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ignasiak DP, McClanahan TB, Bousley RE, Juneau PL, Gallagher KP. Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog. J Thromb Thrombolysis. 1998 Nov;6(3):199-206. doi: 10.1023/A:1008806312396. PMID: 10751802.
2: A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. Eur Heart J. 1997 Sep;18(9):1416-25. doi: 10.1093/oxfordjournals.eurheartj.a015467. PMID: 9458447.
3: Linder R, Oldgren J, Egberg N, Grip L, Larson G, Siegbahn A, Wallentin L. The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease. Eur Heart J. 1999 Apr;20(7):506-18. doi: 10.1053/euhj.1998.1336. PMID: 10365287.
4: Teger-Nilsson AC, Bylund R, Gustafsson D, Gyzander E, Eriksson U. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. Thromb Res. 1997 Jan 15;85(2):133-45. doi: 10.1016/s0049-3848(96)00230-7. PMID: 9058487.
5: Andersen K, Dellborg M, Emanuelsson H, Grip L, Swedberg K. Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment. Coron Artery Dis. 1996 Sep;7(9):673-81. doi: 10.1097/00019501-199609000-00009. PMID: 8950498.
